
The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
Roche Pharmaceuticals (Basel, Switzerland, www.roche.com) has named Severin Schwan, PhD, the current head of diagnostic division, new chief executive.
Roche Pharmaceuticals (Basel, Switzerland,






